"Given the complexities of life sciences, the industry needs more dynamic data and access to therapeutic endpoints to help understand disease progression and comparative effectiveness," said Matthew A. Michela, CEO and President, Life Image. "The availability of Real World Imaging(tm) as part of Life Image's access to clinical touchpoints in its global network combined with the advisory talent and technology of Graticule can help reduce the time and cost of getting life-saving medicines to patients."
About Graticule
Graticule provides data subscriptions and on-demand data collaborations to pharma clients to unlock the value in advanced real world data such as imaging, genomics, and free text notes. Graticule provides extensions to technologies with mature adoption within health systems to eliminate IT overhead and to accelerate the data collaboration process. Graticule is focused on curating data resources and applications for Neurology, Cardiology, Oncology and Rare Diseases. Uses of Graticule data by life sciences clients include machine learning model development, biomarker development, clinical trial recruitment, and identification of undiagnosed patients. For more information, visit Graticule at www.graticule.life.
About Life Image
Life Image is the world's largest medical evidence network providing access to points of care and curated clinical and imaging data. It is the only company in the market today with Real World Imaging(tm) that provides large-scale, heterogeneous, de-identified imaging sets that are linkable to other longitudinal data. Founded in 2008, Life Image has created a digital platform using industry-leading interoperability standards to connect 10,000 facilities with more than 150,000 U.S. providers and 58,000 global clinics. Its network of hospitals, physicians, patients, life sciences, medical devices and telehealth is interconnected with a technical ecosystem of EHRs, PACS, AI solutions, cloud environments and analytics platforms.
Back to HCB News
